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Objectives: In a new experimental model of carbapenemase-producing Klebsiella pneumoniae osteomyelitis
we evaluated the efﬁcacy of colistin alone and in various combinations and examined the emergence of colistin-
resistant strains and cross-resistance to host defence peptides (HDPs).
Methods: KPC-99YC is a clinical strain with intermediate susceptibility to meropenem (MIC"4mg/L) and full
susceptibility to gentamicin, colistin and tigecycline (MICs"1mg/L) and fosfomycin (MIC"32mg/L). Time–kill curves
were performed at 4% MIC. Osteomyelitis was induced in rabbits by tibial injection of 2%108 cfu. Treatment started
14days later for 7days in seven groups: (i) control; (ii) colistin; (iii) colistin!gentamicin; (iv) colistin! tigecycline;
(v) colistin!meropenem; (vi) colistin!meropenem! gentamicin; and (vii) colistin! fosfomycin.
Results: In vitro, colistin was rapidly bactericidal, but regrowth occurred after 9h. Combinations of colistin with
meropenem or fosfomycin were synergistic, whereas combination with tigecycline was antagonistic. In vivo, co-
listin alone was not effective. Combinations of colistin with meropenem or fosfomycin were bactericidal
(P,0.001) and the addition of gentamicin enhanced the efﬁcacy of colistin!meropenem (P"0.025). Tigecycline
reduced the efﬁcacy of colistin (P"0.007). Colistin-resistant strains emerged in all groups except coli-
stin! fosfomycin and two strains showed cross-resistance to HDP LL-37.
Conclusions: In this model, combinations of colistin plus meropenem, with or without gentamicin, or colistin
plus fosfomycin were the only effective therapies. The combination of colistin and tigecycline should be adminis-
tered with caution, as it may be antagonistic in vitro and in vivo.
Introduction
The dramatic spread of carbapenemase-producing Enterobacteriaceae
(CPE) is a global health problem and has been recently
categorized by the WHO as a critical priority.1 These organisms
aremostly responsible for urinary tract, bloodstreamand surgical
site infections and pneumonia in hospitalized patients.2 Post-
traumatic or post-operative osteomyelitis and prosthetic joint
infection (PJI) due to CPE have been more recently described in
countries where CPE is endemic or in hospitals receiving
patients from endemic areas.3,4 Treatment of these infections is
especially difﬁcult because they present a combination of the
main current challenges in the ﬁeld of antibiotics. First, despite
the recent approval of new compounds, such as ceftazidime/
avibactam, therapeutic options remain scarce and could rely on
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old antibacterial agents with limited clinical data on their
efﬁcacy and a high risk of adverse events. Second, osteomyelitis
is a difﬁcult-to-treat infection because of the presence of bioﬁlm5
and impaired diffusion ofmost antibiotics within bone tissues.6
Colistin is often one of the remaining options for carbapenemase-
producing Klebsiella pneumoniae.7,8 However, parenteral admin-
istration of colistin may be a source of adverse effects, including
nephrotoxicity and neurotoxicity.7 Moreover, the emergence of
colistin-resistant strains has been described in patients treated
with colistin,9 possibly promoted by suboptimal drug exposure
due to the low colistin therapeutic index,10,11 and this outcome
may leave patients with no antibiotics left to treat life-
threatening infections, as recently reported by the CDC.12
Basedmostly on cohort studies, experts recommend a combin-
ation of two active agents for the management of severe CPE
infections, primarily colistin combined with meropenem if the MIC
is 8mg/L and/or an aminoglycoside, tigecycline or fosfomycin,
based on in vitro susceptibility tests.13,14
Optimal treatment is poorly deﬁned and it is critical to develop
experimental models that closely reproduce human infections to
provide direct comparisons of therapeutic regimens currently
available for these difﬁcult-to-treat infections with limited thera-
peutic options. Most models of CPE infections described in the
literature are acute murine models of pneumonia, thigh infection
or septicaemia.15–17 Our primary objective was to test the efﬁcacy
of various colistin-based combinations in a new subacute osteo-
myelitismodel due to a KPC-producing K. pneumoniae.
In addition, given that (i) cross-resistance to colistin and host
defence peptides (HDPs) LL-37 and lysozyme has been previously
described18 and (ii) we previously demonstrated the emergence of
cross-resistance to HDPs and daptomycin in an experimental
model of PJI in rabbits, 19,20 we investigated the emergence of
colistin-resistant strains in untreated and treated rabbits with
osteomyelitis and cross-resistance toHDPs.
Materials and methods
Bacterial strain
K. pneumoniae KPC-99YC is a clinical strain with intermediate susceptibility
to meropenem (MIC"4mg/L) and full susceptibility to gentamicin, colistin
and tigecycline (MICs"1mg/L) and fosfomycin (MIC"32mg/L). This strain
produces KPC-2 carbapenemase and belongs to the epidemic clone
ST-258.
Before induction of the animal model of infection, the KPC-producing
strain was cultured in casein hydrolysate-yeast extract-containing (CCY)
broth medium at 37C for 18h. After centrifugation, the pellets were
washed twice and resuspended in PBS before inoculation. All inocula were
quantiﬁed by plating serial dilutions on tryptic soy agar (bioMe´rieux,
La Balme-les-Grottes, France).
Time–kill curve studies
The bactericidal activities of colistin,meropenem, gentamicin and fosfomy-
cin, alone or in combination, were determined in duplicate or triplicate.
Overnight cultures were diluted in 10mL of fresh Mueller–Hinton broth to
yield an inoculumof105 cfu/mL as often recommended formacrodilution
time–kill assays and corresponding to the bacterial load in bones.21–23 The
antibiotic concentrations used were equivalent to 4% MIC.24 After 0, 3, 6, 9
and 24h of incubation in a shaking water bath at 37C, serial dilutions of
0.1mL samples were subcultured on Mueller–Hinton agar plates (Bio-Rad,
Marnes la Coquettes, France) and incubated at 37C for 24h before the
numbers of cfu were counted. A bactericidal effect was deﬁned as a
.3 log10 cfu decrease compared with the initial inoculum. Synergy was
deﬁned as a decrease of .2 log10 cfu/mL for the combination compared
with that of its most active constituent. Antagonism was deﬁned as an in-
crease of .2 log10 cfu/mL for the combination compared with that of its
most active component.
Selection of antibiotic doses in rabbits
Plasma antibiotic concentrations were measured in uninfected rabbits to
select doses leading to plasma concentrations equivalent to those obtained
in humans. Eachantibioticwas tested on oneor several groups of four unin-
fected rabbits (n"16 for colistin and12 formeropenem). After 24h of treat-
ment (steady-state concentrations), blood samples were drawn 15min
and 1, 2, 4, 6, 8 and 12h after the injection and centrifuged, and plasma
was frozen until assayed.
Gentamicin concentrations were determined using an enzyme im-
munoassay, kinetic interaction of microparticles in solution (KIMS), on a
Roche Cobas system (Roche Diagnostics, Mannheim, Germany).
Meropenem, fosfomycin, tigecycline and colistin were analysed by HPLC-
tandemMS using an electrospray ionizationmethod. For meropenem, fos-
fomycin and tigecycline, the HPLC system was interfaced with a triple-
stage quadrupole spectrometer Finnigan TSQ Quantum Discovery Max
from Thermo Fisher (Waltham, USA). Reversed-phase chromatography
was performed on an AtlantisV
R
T3 dC18 column (3lm, 2.1%100mm;
Waters, Milford, USA). The lower limits of quantiﬁcation were 1, 2 and
0.25mg/L for meropenem, fosfomycin and tigecycline, respectively.
Colistin was analysed using a triple-stage quadrupole spectrometer
Acquity H Class-Quattro Premier XE from Waters. The samples were puri-
ﬁed by solid-phase extraction on OASIS HLB Cartridges (Waters) and separ-
ation was performed on a C18 XBridge
TM column (3.5lm, 2.1%100mm;
Waters). The transitions of the [M!3H]3! precursors to the product ions
werem/z 390.82.100.73,m/z 386.18.100.73 andm/z 402.16.100.85 for
colistin A, colistin B and polymyxin B, respectively. The concentration range
was 62.5 to 8000ng/mL for colistins A!B.
Pharmacokinetic parameters were calculated using Monolix version
2016R1 (Lixoft SAS, Antony, France).
Rabbit osteomyelitis model
The method of Norden25 was used to induce osteomyelitis in female New
Zealandwhite rabbits, eachweighing 2 to 3kg. The rabbitswere housed in in-
dividual cages and received food and water ad libitum. The experimental
protocol complied with French legislation on animal experimentation and
was approved by the Animal Use Committee of Maisons-Alfort Veterinary
School. The animals were anaesthetized by intramuscular (im) injection of
ketamine (25mg/kg; Vibrac, Carros, France) and 2% xylazine (25mg/kg;
Bayer Sante´, Puteaux, France). Infection was induced by tibial intramedullary
injection of a sclerosing agent, 0.1mL of 3% sodium tetradecyl sulphate
(Kreussler Pharma, La Chausse´e-Saint-Victor, France), followed by 0.2mLof a
KPC-99YC inoculum (109cfu/mL) and 0.1mL of saline. Patch analgesia with
fentanyl (Janssen-Cilag, Issy-lesMoulineaux, France)was given for 7days fol-
lowing surgery. A 109cfu/mL inoculum was selected because preliminary
experiments (data not shown) revealed that it induced persistent osteomye-
litis in 90% of animals,with lowsepsis-related earlymortality (,10%).
Treatment and its evaluation
Rabbits were randomly assigned to one of seven groups of 12 rabbits:
(i) control; (ii) colistin 150 000IU/kg q8h im (equivalent to 3million IU q8h in
humans); (iii) colistin!gentamicin 30mg/kg im q24h (5mg/kg q24h in
humans); (iv) colistin! tigecycline 14mg/kg imq12h (50mgq12h inhumans);
(v) colistin!meropenem 80mg/kg subcutaneously (sc) q8h (250mg q8h in
humans); (vi) colistin!meropenem!gentamicin; and (vii) colistin! fosfomycin
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150mg/kg q12h im (4g q8h in humans). The same dose of colistin was
used in all groups. Each regimen was started 14days after surgery and
administered for 7days. Rabbits with no osteomyelitis and those that died
before surgery, due to anaesthesia, or before the start of treatment were
not included (Table S1, available as Supplementary data at JACOnline).
Rabbits were euthanized by intravenous (iv) injection of pentobarbital
3days after the endof therapy (day24post-infection) to allow for bacterial re-
growth after treatment discontinuation. Control rabbits were also euthanized
on day 24. At the time of death, the upper third of the tibia (3cm long), includ-
ing compact bone and marrow, was isolated, split with a bone crusher,
weighed, cut into small pieces, frozen in liquidnitrogenandcrushed inanauto-
pulverizer (Spex 6700; Freezer/Mill Industries Inc., Metuchen, USA). The pulver-
ized bonewas suspended in 10mL of sterile saline. Serial dilutionsweremade
and plated on tryptic soy agar. After 24h of incubation at 37C, the number of
viable microorganisms was determined. The results were expressed as the
median (IQR) log10cfu/g of bone andas the percentage of animalswith sterile
bones. Bone was considered sterile when the culture showed no growth after
incubation for 48h at 37C and the number of cfuwas recorded as the lowest
detectable bacterial count (1.10 to 1.30cfu/g of bone, depending on the
weight of the sample). Analyses were performed including all animals that
receivedat least onedoseof the treatmentassigned.
In vivo selection of mutants
Each undiluted bone homogenate (50lL) of untreated and treated rabbits
was plated onto Mueller–Hinton II agar and onto Mueller–Hinton II agar
supplementedwith colistin (0.125, 0.25, 0.5, 1, 2, 4 or 16mg/L) to detect re-
sistant mutants after 24h of incubation at 37C. When bacterial growth
was observed, K. pneumoniae identiﬁcation was conﬁrmed using MALDI-
TOF MS (VITEK MS; bioMe´rieux, La Balme-les-Grottes, France). The MIC val-
ues of colistin were determined by liquid broth dilution methods based on
the UMIC kit (Biocentric, Bandol, France). Resistant mutants were deﬁned
by an MIC value .2mg/L (i.e. MIC increased by at least 2-fold compared
with that for the initial strain).
Genetic characterization of colistin-resistant strains
Mgr protein is involved in the regulation of LPS biosynthesis in
K. pneumoniae.26 Mutations in themgrB gene are key elements as a source
of acquired resistance to colistin in K. pneumoniae.27 Therefore, alterations
in the mgrB gene sequences were sought in colistin-resistant strains that
emerged in control or treated rabbits. The mgrB genes of four colistin-
resistant isolates were ampliﬁed with pre-mgrBF and mgrB-extR primers
and sequenced as reported.27
Cross-resistance to human antimicrobial peptides
(AMPs)
Colistin-resistant bacteria were tested for their susceptibility to speciﬁc
AMPs produced by human cells in response to infections or wounds and by
inﬁltrating neutrophils: LL-37, human a-defensin 5 (HDA5) and human b-
defensin 3 (HDB3).26
Approximately 1000cfu of mid-logarithmic phase bacteria were incu-
batedwith 0, 0.3125, 0.625, 1.25, 2.5, 5, 10 and 20mg/L diluted peptide for
2h in a 96-well plate at 37C in PBS supplemented with 1% LB broth. The
upper limit of 20mg/L peptide was based on previous studies,28,29 which
showed less than 20% survival at this concentration. Sampleswere plated in
triplicate on LB agar plates to quantify the remaining bacteria by cfu counts
and the assayswere run at least in duplicate for each peptide concentration.
Themeans and standard deviationswere calculated for each condition.
Data analysis
The data were analysed with R software.30 Due to the small sample size
and asymmetric distributions of variables, exact non-parametric tests
implemented in the coin package were used.31 Data of numeric variables
were summarized by the minimum, maximum, median, range, IQR, mean
and standard deviation, and data of categorical variables by numbers and
percentages. Between-group comparisonswere performed using appropri-
ate statistical tests. The v2 test, Fisher’s exact test and the Kruskal–Wallis
non-parametric method were used. The effect of antibiotics and their 95%
CIs on log10 cfu criteria were calculated by the Hodges–Lehmann estimator
and the Bauer algorithm, respectively. The effect of the antibiotics on the
sterility criteria was estimated by the difference in the proportion of sterile
bones and the 95% exact CI. A P value ,0.05 was considered statistically
signiﬁcant.
Results
In vitro bactericidal effect
Time–kill curves obtained at 4%MIC (Figure 1) showed that colistin
alone was rapidly bactericidal during the ﬁrst 6h. However, re-
growth occurred after 9h of incubation. The MICs for isolates
obtained after regrowth were similar to the MICs for the initial
strain. Meropenem alone was slowly bactericidal, with a decrease
in the initial inoculumby only 2 log10 at 9h. Fosfomycin and genta-
micin alone exhibited early bactericidal activity, but regrowth was
observed at 3 and6h, respectively.
For the combination of gentamicin and colistin, rapid bacteri-
cidal activity was observed (with a complete bactericidal effect up
to 2h), but regrowth was observed after 3h. When fosfomycin
was added to colistin, rapid bactericidal activity was observed
(as with colistin alone). However, this combination of antibiotics
prevented regrowth. The combination of colistin, meropenem
and gentamicin was the most effective combination, with a fast
and complete bactericidal effect at 3h and no subsequent
regrowth.
Tigecycline alone was not bactericidal and slight regrowth was
observed at 9h (Figure 2). The combination of tigecycline and colis-
tin was antagonistic, with a loss of the initial bactericidal effect
observed with colistin alone. A dose-dependent decrease of bac-
tericidal activity for the combination was observed when a range
of tigecycline concentrations (2-fold serial dilutions, from 32 to
4mg/L) with a ﬁxed concentration of colistin (4%MIC) were tested
(data not shown).
Serum concentrations of meropenem and colistin in
rabbits
For colistin, the pharmacokinetic/pharmacodynamic target (AUC/
MIC ratio of 25–50) was achieved with the dosing regimen of
150 000 IU three times daily im, equivalent to 3M IU q8h in
humans. For meropenem, the initial target (T.MIC 50%) was
achieved with 250mg/kg q8h, but the treatment induced severe
diarrhoea and lethality of .50%. With a dosage of 80mg/kg q8h
sc (T.MIC 20%), the plasma mean Cmax and mean Cmin were
17.9+12.4 and 0.35+0.11mg/L, respectively. These values were
comparable to the Cmax and Cmin values observed with 250mg
q8h in humans. For gentamicin, the pharmacokinetic/pharmaco-
dynamic parameter target (Cmax"10%MIC) was achieved with a
dosage of 30mg/kg q24h im. For fosfomycin, Cmax and AUC values
of 400mg/L and 1128mgh/L, equivalent to 4g q8h in humans
and allowing a T.MIC of .50%, were obtained with 150mg/kg
q12h im dosage. For tigecycline, the pharmacokinetic/
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Figure 1. In vitro killing curves for carbapenemase-producing K. pneumoniae strain KPC-99YC using various antibiotics alone (a) or in combination
(b) at concentrations equivalent to 4%MIC. Experiments were performed in duplicate or triplicate.
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Figure 2. In vitro killing curves for carbapenemase-producing K. pneumoniae strain KPC-99YC using colistin and tigecycline alone and in combin-
ation at concentrations equivalent to 4%MIC. Experiments were performed in duplicate.
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pharmacodynamic target (AUC/MIC ratio .18) was achieved with
a dosage of 14mg/kg q12h im.
Therapeutic studies
In control rabbits at day 24, the median (IQR) of bacterial counts
was 6 (5.8–6.4) log10 cfu/g of bone.
Comparedwith thoseof controls (Figure3aandFigure4), bacterial
counts in rabbits treatedwith colistin alonewere not different, with a
median (IQR) of 5.5 (4.3–6.2) log10cfu/g of bone (P"0.106) and no
sterile bones at day 24 (Figure 3b). Colistin combined with
meropenemor gentamicin or fosfomycin or combinedwithmerope-
nem!gentamicin signiﬁcantly decreased bone bacterial concentra-
tions. In accordance with time–kill curves, the triple combination of
colistin plus meropenem plus gentamicin was more effective
than colistin plus meropenem and colistin plus gentamicin on
bone bacterial density (Table 1) and was the only effective regi-
men for bone sterilization (Figure 3b). Notably, as observed
in vitro with time–kill curves, an antagonist effect was observed
with colistin plus tigecycline, which was signiﬁcantly less effect-
ive than colistin alone on bone bacterial concentrations
(P"0.007) (Table 1).
–5
Control
Groups N
13 6 (5.75, 6.44)
Colistin alone 11 5.5 (4.29, 6.15)
Colistin + gentamicin 11 4.99 (4.63, 5.6)
Colistin + tigecycline 11 6.58 (6, 7.25)
Colistin + meropenem
Colistin + meropenem + gentamicin
12
10
4.55 (3.91, 5.25)
1.48 (1.45, 3.98)
Colistin + fosfomycin 11 3.97 (3.22, 4.6)
–0.61 (–1.81, 0.14)
– –
–1.04 (–1.75, –0.34)
0.62 (–0.16, 1.39)
–1.53 (–2.38, –0.78)
–4.39 (–4.85, –1.59)
–2.03 (–2.88, –1.36)
0.106
0.003
0.096
< 0.001
< 0.001
< 0.001
Median log10 cfu (IQR) Effect size (95% CI)
Bacterial load reduction in log10 cfu
P
–3 –1 1
In favour of controlIn favour of treatment
30
(a)
Figure 3. Effect of colistin alone or in combination with various antibiotics on log10 cfu/g of bone (a) and on percentage of sterile bones (b) in animals
with carbapenemase-producing K. pneumoniae (strain KPC-99YC) experimental osteomyelitis.
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Colistin-resistant mutants
Colistin-resistant mutants emerged in rabbits treated with colistin
[n"2; L31 and L35 (MICs"64mg/L)], colistin!gentamicin [n"3;
L37, L43 and L48 (MIC"64, 64 and 16mg/L, respectively)], coli-
stin! tigecycline [n"2; L57 (MIC"16mg/L) and L59 (MIC"64mg/L)]
and colistin!meropenem!gentamicin [n"1; L74 (MIC"32mg/L)].
Notably, colistin-resistant strainswerealsodetected inoneuntreated
rabbit at day 24 [L17 (MIC"8mg/L)].
Characterization of colistin-resistant strains
Mutation in the mgrB gene
As colistin resistance was unstable in vitro, selected colistin-
resistant strains were subcultured on Mueller–Hinton II agar with
2mg/L colistin before ampliﬁcation of the mgrB gene by PCR and
sequencing. MgrB proteins frommutant L35 (from a rabbit treated
with colistin alone) and mutant L59 (from a rabbit treated with
colistin! tigecycline) were truncated. For strain L35, the trunca-
tionwas due to insertion of an ISKpn26-like sequence in the coding
sequence of the gene, whereas for strain L59 the truncation was
due to a nucelotide substitution responsible for a premature stop
codon (Table 2). For strain L37 (from a rabbit treated with coli-
stin!gentamicin), no amplicon was obtained with mgrB primers,
suggesting either a complete deletion of the mgrB gene or muta-
tions in regions corresponding to the binding of the primers used
for ampliﬁcation of themgrB gene (Table 2). Finally, themgrB gene
was partially deleted in the L17 control rabbit. Other resistant
strains (L31 and L57) had aWTmgrB gene, suggesting other chro-
mosomally encoded resistancemechanisms (Table 2).
Cross-resistance to host AMPs
Colistin-resistant strains that emerged in control rabbits [L17
(MIC"8mg/L)] had a slightly increased resistance to LL-37 with
decreased susceptibility at 10mg/L comparedwith the initial strain
Groups
Control
Colistin alone
13
11
0
0
Colistin + gentamicin 11 1 (9.1)
Colistin + tigecycline 11 0
Colistin + meropenem 12 1 (8.3)
Colistin + meropenem + gentamicin 10 7 (70)
Colistin + fosfomycin
>0.999
0.458
>0.999
0.48
<0.001
>0.999
0 (–24.7, 28.5)
––
9.1 (–15.6, 41.3)
0 (–24.7, 28.5)
8.3 (–16.2, 38.5)
70 (33.8, 93.6)
0 (–24.7, 28.5)11 0
–50
In favour of control In favour of treatment
0 50 100
N Sterile bone (%) Effect size (95% CI)
Difference between proportion of sterile bones
P
(b)
Figure 3. Continued.
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(Figure 5). HDB3 and HDA5 showed lower toxicity, as previously
observed, and no difference was observed between the parental
strain KPC-99YC and the colistin-resistant KPC-99YC derivatives
(Figure 5). The colistin-resistant strain L31, with a colistin MIC of
64mg/L, that emerged in a rabbitwith osteomyelitis treated by co-
listin alone was not susceptible to LL-37 even at a high concentra-
tion, in contrast to the initial parental strain (Figure 5).
Discussion
The efﬁcacy of colistin in bone infections due to Gram-negative
bacilli is poorly known. Our work showed that the efﬁcacy of colis-
tin alone or in combination, in a new subacute stringent model of
KPC-producing K. pneumoniae osteomyelitis, was limited.
Monotherapy with colistin was ineffective and colistin-resistant
strains emerged after 14days of treatment. The addition of genta-
micin, fosfomycin or meropenem was the only effective therapy.
The triple combination of colistin!meropenem!gentamicin was
the only regimen able to sterilize most animals. However, colistin-
resistant strains emerged in all groups, except in rabbits treated
with colistin! fosfomycin. Notably, the suppression of colistin-
resistant strains by fosfomycin has been described in time–kill
experiments by others and this effect could be due to the killing of
colistin-resistant strains by fosfomycin.32
The ﬁndings regarding osteomyelitis are in line with clinical
observations and with recommendations for the treatment of
other CPE infections.14,33 Indeed, those expert recommendations,
based mostly on retrospective or prospective non-comparative
clinical studies, state that: (i) colistin should always beused in com-
bination with other drug(s); and (ii) penems should be included in
the combinationwhen theMIC is8mg/L.
The combinationof colistin and tigecycline is often used for treat-
ing severe KPC-producing K. pneumoniae infections, as tigecycline
often remains active in vitro. Notably, our data highlighted that this
combination was less bactericidal against KPC-99YC than colistin
alone, suggesting an antagonistic effect in vivo. These data are in
agreement with those provided by in vitro time–kill curves with KPC-
99YC. The antagonistic effect of the tigecycline! colistin combin-
ation has already been described in vitro with other CPE, including
NDM1-producing Enterobacteriaceae,34 and in vivo in a thigh infec-
tionmodel of KPC-producing Enterobacteriaceae.35 Thismay be due
to themechanisms of action of tigecycline and colistin, i.e. inhibition
of protein synthesis, interaction with LPS and DNA biosynthesis,
which may be antagonistic. The experiments performed with two
other KPC-producing K. pneumoniae (data not shown) belonging to
distinct clonal complexes suggested that the antagonist effect may
be strain-dependent anddeserves to be testedwhena clinical strain
is isolated before the use of such a combination.
An interesting ﬁnding of this work is that our in vivo results mir-
ror in vitro time–kill curves performed with logarithmic-growth
phase bacteria. This result, which was also found by others in a
foreign-body experimental model due to ESBL-Escherichia coli,36
contrasts with results obtained with MRSA experimental implant-
related infections, where the in vivo efﬁcacy of antibiotics on MRSA
is correlated with the bactericidal activity of antibiotics on station-
ary-growth phase bacteria.37 This ﬁnding suggests that in sub-
acute infections such as osteomyelitis, the in vivo adaptation of
the organisms to the local environment depends on the bacterial
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Figure 4. Bacterial density (log10 cfu/g of bone) of colistin alone or in
combination with various antibiotics for the treatment of carbapene-
mase-producing K. pneumoniae experimental osteomyelitis due to strain
KPC-99YC. Whiskers are the minimum and the maximum values and the
horizontal line in each box plot, which covers the IQR, is the median.
Table 1. Pairwise comparisons of colistin in combination with vari-
ous antibiotics in carbapenemase-producing K. pneumoniae (strain
KPC-99YC) experimental osteomyelitis
Antibiotics
Difference in
log10 cfu (95% CI) P
Colistin!meropenem!
gentamicin compared with:
colistin!gentamicin #3.2 (#4.07 to#0.09) 0.024
colistin! tigecycline #4.58 (#5.73 to#2.43) ,0.001
colistin!meropenem #2.58 (#3.61 to#0.1) 0.025
colistin! fosfomycin #1.86 (#3.07–0.34) 0.095
Colistin!gentamicin compared
with:
colistin! tigecycline #1.63 (#2.63 to#0.87) ,0.001
colistin!meropenem 0.5 (#0.32–1.49) 0.267
colistin! fosfomycin 1.04 (0.14–1.92) 0.019
Colistin! tigecycline compared
with:
colistin!meropenem 2.23 (1.28–3.17) ,0.001
colistin! fosfomycin 2.72 (1.93–3.59) ,0.001
colistin alone 1.24 (0.33–2.6) 0.007
Colistin!meropenem compared
with:
colistin! fosfomycin 0.52 (#0.37–1.37) 0.184
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species. The concordance between in vitro and in vivo results, as
well as the strain-dependent antagonistic effect of tigecycline
combined with colistin, suggests that in vitro time–kill curves could
be a useful tool to select the best therapeutic combination for se-
vere KPC-producing K. pneumoniae infections.
Finally, we documented the treatment-induced emergence of
colistin-resistant strains. As already described for several
K. pneumoniae strains fromhumans treatedwith colistin,27 this co-
listin resistance trait was mostly due to mutation/deletion in the
mgrB gene involved in LPS biosynthesis. Interestingly, resistance to
colistin was also observed in one untreated rabbit. As cross-
resistance to colistin (i.e. a cationic peptide) and host antimicrobial
cationic peptides has already been described in Gram-negative
bacilli,26,38 we investigated the co-occurrence of resistance to
HDPs among those strains. The data showed that, in contrast to
previous ﬁndings,26 some colistin-resistant strains isolated in ani-
mals with osteomyelitis 24days post-infection have slightly
increased resistance to LL-37, which was enhanced after colistin
treatment. This adaptation to the local host environment has al-
ready been described with staphylococci in our PJI model.19,20 The
spontaneous emergence of resistance to AMPs could play a role in
PJI persistence, as HDPs are the ﬁrst line of host defence against
pathogens.39 This cross-resistance may contribute to the emer-
gence of colistin resistance in patients treated with colistin, as co-
listin exposure ampliﬁes this phenomenon.
Our study has limitations. First, we used a low dose of merope-
nem (80mg/kg im q8h, equivalent to only 250mg iv q8h in
humans) due to poor tolerability of higher doses in rabbits. Hence,
we could not replicate pharmacokinetic/pharmacodynamic tar-
gets for meropenem in humans as initially planned and the efﬁ-
cacy of meropenem in vivo may have been underestimated. As
meropenem enhances the efﬁcacy of colistin in vivo at this sub-
optimal dosage, this limitation strengthens the potential interest
of this combination, as meropenem doses used in humans are
much higher. The second major limitation of our study is that we
used only a single strain. Hence, our ﬁndings may not be extrapo-
lated to any CPE, especially strainswith penemMICs.8mg/L.
In conclusion, our ﬁndings highlight that colistin monotherapy
should not be recommended for treating KPC-producing
Enterobacteriaceae osteomyelitis owing to its poor in vivo efﬁcacy
and the emergence of resistant strains. For strains with MIC
8mg/L, combinations of colistin and meropenem, with or with-
out gentamicin, could be effective, but did not completely prevent
the emergence of colistin-resistant strains. The combination of
Table 2. Analysis of themgrB gene sequences in the parental KPC-99YC strain that is susceptible to colistin inoculated into rabbits and some co-
listin-resistant strains that emerged in controls and treated rabbits with KPC-99YC osteomyelitis sacriﬁced 24days post-infection
Isolate Treatment Colistin MIC (mg/L) mgrB gene
KPC-99YC parental strain 0.25 WT
L17 none (control) 8 partial deletion
L31 colistin 64 WT
L35 colistin 64 insertion of an ISKpn26-like sequence into the
coding sequence
L37 colistin!gentamicin 64 total deletion
L57 colistin! tigecycline 16 WT
L59 colistin! tigecycline 64 truncated (stop codon)
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Figure 5. Percentage of bacterial survival as a function of peptide con-
centration. Panels show data for the initial strain (KPC-99YC) and colis-
tin-resistant K. pneumoniae strains. Data represent the experimental
means (symbols)+ standard errors of the mean (vertical bars) for cat-
ionic AMPs LL-37 (squares), HDA5 (circles) and HDB3 (triangles).
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colistin and fosfomycin appears promising and should be further
evaluated in vivo. The combination of colistin and tigecycline
should be administered with caution, as it may be antagonistic
in vitro and in vivo. Experimental stringent models such as bone
and joint infections may improve our knowledge for designing opti-
mal treatment of CPE, including KPC-producing Enterobacteriaceae,
and better inform clinical recommendations. The concordance be-
tween in vitro and in vivo bactericidal activity may be used as a tool
to screen optimal combinations for selected clinical isolates and de-
sign individualized regimens for the treatment of difﬁcult-to-treat
CPE infections.
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